Press Release
-
EG BioMed Supports Pancreatic Cancer Awareness at PurpleStride 2025
EG BioMed was honored to sponsor and participate in PurpleStride 2025, hosted by the Pancreatic Cancer Action Network (PanCAN) on April 26, 2025. The event served as a powerful platform to raise awareness about pancreatic cancer and promote innovation in early detection. The event gathered pancreatic cancer patients, families, clinicians, researchers, and supporters from across…
-
EG BioMed to Present Research on Methylation-Based Blood Tests for Cancer Detection and Screening applications
CHICAGO – April 28–29, 2025 – EG BioMed, a biotechnology company specializing in early cancer detection using methylated circulating cell-free DNA, today announced that it will present three scientific abstracts at the upcoming American Association for Cancer Research® (AACR) Annual Meeting 2025. These studies highlight the use of DNA methylation biomarkers for non-invasive cancer detection…
-
The Best Partner for Entering the U.S. Precision Medicine Market: EG BioMed CLIA-Certified Laboratory
In the highly competitive U.S. precision medicine market, partnering with a reliable CLIA-certified laboratory is a key advantage for businesses seeking to rapidly enter the market. EG BioMed’s CLIA-certified laboratory partnership program offers a strategic solution to overcome market bottlenecks and quickly establish a foothold in the U.S. precision medicine sector. (SeeMore) Comprehensive Regulatory Compliance…